Up to half of patients with ALS develop cognitive impairment during the course of the illness. Despite this, there is no simple tool for screening patients in the clinical setting. This study examines the sensitivity, specifi city and accuracy of the ALS Cognitive Behavioral Screen (ALS-CBS ™). We administered the measure to 112 ALS patients, including 31 who also underwent comprehensive neuropsychological testing. Screen results were validated by determining the accuracy against the full battery. Optimal cut-off scores for predicting the correct diagnosis were determined, and mean scores were compared between patients, controls and different diagnostic groups. The results demonstrated that mean cognitive scores differed between ALS and normal controls ( p Ͻ0.0001). The cognitive section differentiated ALS-FTD from other ALS patients with 100% accuracy. Cognitively normal ALS patients could be distinguished from those with any cognitive defi cit with 71% specifi city and 85% sensitivity. A separate behavioral score was signifi cantly lower in the ALS cohort compared to controls ( p Ͻ0.0001) and predicted ALS-FTD with 80% sensitivity and 88% specifi city. In conclusion, the ALS-CBS™ can aid in detecting cognitive and behavioral impairment in a clinical setting, although it does not replace formal diagnostic assessment. Further validation with larger sample sizes will clarify its clinical utility.
Introduction
Up to half of patients with amyotrophic lateral sclerosis (ALS) develop cognitive impairment during the course of their disease while estimates of the prevalence of patients fulfi lling criteria for frontotemporal dementia (FTD) range from 15% to as high as 41% (1,2). Other estimates suggest that at least 17% of patients demonstrate frontally-mediated behavioral changes during the course of their illness, often independent of cognitive decline (3). These impairments are associated with shortened survival and poor compliance with interventions (4) .
Despite the high frequency, formal clinical strategies for discerning which patients have developed impairments are lacking. Comprehensive neuropsychological test batteries are considered the gold standard for diagnosis, but they are time consuming and fatiguing for patients, and are expensive for routine use in ALS clinics. At the other end of the spectrum are simple word generation tasks. These have already been employed as screening tools for cognition but they do not assess behavior and evaluate only a narrow aspect of cognitive function (1, 5) . Two intermediate-sized screening batteries have been considered as well (6,7), utilizing a number of existing measures developed for non-ALS patient populations. With administration times of 20 -30 minutes, they are more practical in a multidisciplinary setting, but neither has been validated against a gold standard or used clinically in more than one center.
Here, we present validation data for the ALS Cognitive Behavioral Screen (ALS-CBS ™). The test aims to detect frontal lobe-mediated cognitive and behavioral changes and is similar in size to the MiniMental State Exam used in global dementias (8). It was developed as an initial tool in the strategy for identifying FTD in the clinical setting. This measure includes a cognitive section adapted from elements of standard testing batteries and a caregiver questionnaire comprising questions sensitive to alterations in personality and behavior. The ALS-CBS ™ can be completed in 5 minutes and can be used with patients regardless of limb or bulbar impairment. This study aims to determine the diagnostic accuracy of the ALS-CBS ™ and to compare screen results across different ALS groups and between patients and controls.
Materials and methods

Screen development
An earlier version of the screen was administered to 150 patients in multiple ALS clinics, and a validation study revealed high sensitivity (9). The screen was modifi ed to the current version (Supplemental fi le 1 -available in the online version of this article) based on an analysis of these results.
The cognitive section measures attention, concentration, working memory, fl uency and tracking ( Figure 1 ). The specifi c items were selected if they required minimal motor and speech involvement or demonstrated high accuracy according to previous ALS studies (1,10). Items were also chosen based on research that identifi ed an association between errors made on specifi c items and the level of cognitive impairment in ALS (2). Hence, the cognitive section records both correct and incorrect responses (Supplemental fi le 2 -available in the online version of this article).
The cognitive section comprises four subscales with a total score of 20. Lower scores refl ect greater impairment. Responses can be provided verbally or in writing and can be generated with speech devices or communicated with eye movements or mouthing. Only the verbal fl uency test is timed. Scoring is based on a combination of scores for each item and the number of errors made.
Behavioral domains ( Figure 1 ) were selected to assess a variety of abnormalities known to occur in ALS and FTD, related to alterations in empathy, personality, judgment, language, and insight (3, 11, 12) . The behavioral section includes 15 caregiver-rated items that assess changes since disease onset. Items are scored from 0 to 3 (large, medium, small, no change). Total scores range from 0 to 45.
Four additional items are completed by the caregiver to track for depression, anxiety, pseudobulbar affect, and fatigue. These questions address factors that may infl uence cognition or behavior but are not necessarily related to frontal lobe degeneration. Endorsement of these items can alert providers to 
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other conditions that may confound the interpretation of testing (13 -15).
Subjects and testing
The current version of the screen was administered to 112 patients at the Forbes Norris Clinic (FNC) (n ϭ 81), University of California, San Francisco (UCSF) ( n ϭ 9) and the Baylor College of Medicine Clinic (BCM) ( n ϭ 22). Thirty-one patients (FNC ϭ 17, BCM ϭ 14) participated in a validation study where the ALS-CBS™ scores were compared to results from a comprehensive neuropsychological battery. In addition, 15 age-matched healthy controls completed the ALS-CBS ™ at FNC. The recruitment period ranged from January 2008 to January 2009 for this IRB-approved, retrospective study.
The ALS-CBS ™ was administered consecutively to patients in each of the three clinics. BCM participants in the validation cohort were chosen consecutively, and FNC participants were chosen if enrolled in an IRB-approved imaging study that required comprehensive neuropsychological testing. Additionally, some patients with ALS-FTD who were selected from FNC completed a neuropsychological battery for diagnostic purposes. The gold standard battery and ALS-CBS ™ were normally administered on the same day by the same examiner. Examiners were blinded to the participant 's diagnostic classifi cation based on the gold standard battery when administering the ALS-CBS ™.
The comprehensive test batteries were similar between the two centers (Table I ) and administered by psychologists experienced in neuropsychological assessment. Each battery was compiled by neuropsychologists with expertise in ALS and included standardized verbal and non-verbal executive tests that assessed verbal fl uency, non-verbal fl uency, set shifting, sequencing, and response inhibition. Additional measures of memory, attention, concentration, mental control, depression and behavior were included at both sites. Test results were adjusted for age, gender and education and patients were then categorized into one of fi ve groups as follows: 1) ALS-normal (no impairment); 2) cognitively impaired (ALSci); 3) behaviorally impaired (ALSbi); 4) cognitively and behaviorally impaired (ALSbici); or 5) ALS-FTD. The classifi cation scheme, which was equivalent across both sites, was based on recent consensus criteria for defi ning these impairments in ALS (33). The Neary criteria were used to diagnose FTD (12).
We used the Frontal System Behavioral Scale (FrSBe) Family Rating Form as a gold standard for behavioral assessment. Change scores were calculated (total current T-score minus total premorbid T-score) to quantify the extent of behavioral alteration since disease onset. This change score was compared to the total ALS-CBS ™ behavioral score.
Clinical and demographic parameters
We recorded age, education, forced vital capacity (FVC), and functional disability using the ALS Functional Rating Scale-Revised (ALSFRS-R) at the time of testing each patient.
Statistics
Patients were categorized into one of the fi ve diagnostic groups based on the neuropsychological battery. Means and standard deviations for the ALS-CBS™ were calculated for each diagnostic group on both the cognitive and behavioral sections. Differences across groups were compared using the nonparametric Kruskal-Wallis test. If this test showed between-group heterogeneity, two-sample Wilcoxon rank-sum (Mann-Whitney) tests were used to test pair-wise differences between diagnostic groups based on the ranks of their ALS-CBS ™ scores. When ALSci, ALSbi, and ALSbici did not differ, they were combined into a single impairment category (ALSimpaired) for comparison against ALS-FTD patients and patients without impairment. Correlations were measured as Kendall's tau-b, a rank correlation that does not assume normal distribution of values. We performed linear regression analysis across patient groups and controls to evaluate the relationship between ALS disease severity and ALS-CBS ™ scores. Furthermore, we calculated sensitivity, specifi city, and positive (PPV) and negative (NPV) predictive value (PPV) for both the cognitive and behavioral score of the ALS-CBS ™ and determined desirable thresholds selected by looking at plots of the data. Accuracy was calculated to determine the percentage of patients that could be correctly assigned to a diagnostic group based on the selected cut-off scores.
Results
ALS-CBS™ scores: ALS cohorts versus controls
The control group had signifi cantly lower education than the ALS cohort ( p ϭ 0.004) (Table II) . However, mean scores for both cognitive and behavioral sections of the ALS-CBS ™ were signifi cantly lower in the ALS cohort ( n ϭ 112) compared to the control group ( p Ͻ0.0001 for both).
The 31 patients who completed the neuropsychological assessment battery did not differ from the control group by age ( p ϭ 0.62) or education ( p ϭ 0.48) ( Table II) . The validation cohort did not differ signifi cantly from the larger ALS cohort although they had relatively lower levels of education that approached signifi cance ( p ϭ 0.06). The 31 ALS patients were classifi ed as normal ( n ϭ 14), ALSci ( n ϭ 5), ALSbi ( n ϭ 3), ALSbici ( n ϭ 3), and ALS-FTD (n ϭ 6). Mean scores on the ALS-CBS ™ for each group are summarized in Table III . The ALS validation cohort scored signifi cantly lower than the control group on both the total cognitive score ( p ϭ 0.0005) and the total behavioral score ( p ϭ 0.0009).
Cut-off scores for the ALS-CBS ™
We assessed optimal cut points for cognition and behavior that differentiated between ALS-FTD and the remainder of the cohort (Figure 2 ). For the cognitive section, a cut-off of equal to or below 10 had 100% sensitivity, specifi city, PPV, and NPV for identifying FTD. For behavior, a cut-off equal to or less than 32 gave 88% sensitivity, 80% specifi city, 94% PPV and 67% NPV. Thus, the cut-off of 10 for cognition achieved 100% accuracy, while the cut-off of 32 for behavior achieved 86% accuracy.
We further assessed the optimal cut-off that could differentiate between ALS-normal and patients with any cognitive defi cit (ALSci, ALSbici, FTD), and again for ALS-normal versus those with any behavioral defi cit (ALSbi, ALSbici, FTD). For cognition, a cut-off score greater than or equal to 17 had 86% NPV and 71% specifi city to exclude cognitive impairment, while scores below 17 had 85% sensitivity and 69% PPV that there would be some cognitive impairment on a full battery. For the behavioral section, a score above 36 has a specifi city of 86% and NPV of 92% for predicting that no behavioral impairment would be endorsed on comprehensive evaluation, while a score equal to or less than 36 has 90% sensitivity and 82% PPV for predicting behavioral impairment. The cognitive cut-off of 17 achieved 77% accuracy, while the cut-off of 36 for behavioral score achieved 86% accuracy.
Comparisons across diagnostic groups
Mean cognitive scores for the ALS-normal, ALSci, ALSbi and ALSbici groups were not statistically different ( p ϭ 0.35 by Kruskal-Wallis test), but the number of patients in each group was small. We did fi nd a signifi cant decrease in both total cognitive and total behavior scores with advancing degrees of cognitive impairment (Figure 2 ). Linear regression of total cognitive and behavioral scores by diagnostic category (separated by controls, ALS-normal, ALS-impaired, and ALS-FTD) was signifi cant (at p Ͻ0.001) for each regression.
In direct group comparisons, we found differences in cognitive scores between ALS-normal ( n ϭ 14) and ALS-FTD ( n ϭ 6) patients ( p ϭ 0.0005). To determine if non-FTD patients differed from normal controls, we collapsed the remaining four diagnostic groups into a single category (ALS, non-FTD) and found that cognitive scores differed signifi cantly from control subjects ( p ϭ 0.008, Mann-Whitney test). ALS, non-FTD also had higher cognitive scores than ALS-FTD ( p ϭ 0.001, Mann-Whitney test). Finally, we grouped ALS patients with any cognitive or behavioral impairment (ALS-impaired, n ϭ 10) and found that mean cognitive scores were lower than ALS-normal, but the difference did not reach signifi cance ( p ϭ 0.15). ALS-impaired did differ signifi cantly from the ALS-FTD group ( p ϭ 0.001).
ALS-CBS ™ behavioral scores did not differ among ALS subgroups without FTD ( p ϭ 0.16 by Kruskal-Wallis test). Mean behavioral scores were again collapsed into one diagnostic group (ALS, non-FTD). Behavioral score differences for the ALS, non-FTD group and controls did not reach signifi cance ( p ϭ 0.14 by Mann-Whitney test). Behavioral scores were marginally greater for the ALS, non-FTD group than for the ALS-FTD cohort ( p ϭ 0.09 by Mann-Whitney test). Behavioral scores were signifi cantly different between ALS-normal, ALS-impaired and ALS-FTD ( p ϭ 0.022 by Kruskal-Wallis test). The difference between ALS-normal and ALS-FTD was significant ( p ϭ 0.005).
Discussion
We developed the ALS-CBS ™ as a simple method to screen patients with ALS for frontally mediated impairments. This preliminary validation study illustrates that the measure has high predictive value for identifying patients with frank FTD and that it can assist in excluding dementia when patients are cognitively and behaviorally normal. The cognitive section differentiated ALS-FTD from other ALS patients with 100% accuracy, while the behavioral portion predicted ALS-FTD with 80% sensitivity and 88% specifi city. Cognitively normal ALS patients could be distinguished from those with any cognitive defi cit with 71% specifi city and 85% sensitivity.
The ALS-CBS ™ improves upon simple word generation tasks that have also been advocated for use in ALS by adding measures of attention, concentration and mental control, and by quanitifying the number of errors (2). In one study where verbal fl uency was used to screen cognition using a cut-off of eight words or less in 1 minute, the sensitivity was 88% but many normal patients scored poorly resulting in a specifi city of only 70% (1). By comparison, the cognitive section of the ALS-CBS ™ had a sensitivity of 85% to detect any cognitive impairment and 100% sensitivity to detect frank ALS-FTD. With our own cohort, 20% of patients who scored below the raw score cut-off of eight words on letter fl uency still had normal total cognitive scores on screening.
Earlier work suggests that cognitive impairment is associated with poor compliance and shortened life span in ALS (4), although it is still not entirely clear at what point meaningful risks begin to accrue. Our fi ndings offer a pathway toward answering this question. Our measure can readily identify a subset of patients with FTD, and excludes abnormalities in most patients with the highest scores. It follows that we begin to capture a third subset of patients with intermediate results, who tend to fi t the recently recommended designations of ALSbi and ALSci. It is likely that these patients are the best candidates for studies that compare outcomes with cognitive declines. Even with relatively small numbers, our analyses found a trend supporting its validity, in that cognitive scores were lower in patients who were diagnosed with ALSci on the larger battery than they were in those that were cognitively normal ( p ϭ 0.09). Assessing greater numbers of patients will help defi ne the exact accuracy of the screen for identifying these mild impairments, but on a practical level, intermediate scores on a screening measure should supplement clinical instincts and draw attention to the possibility of impairment.
It is not surprising that the behavioral portion was less accurate than the cognitive portion. In general, interpretation of behavioral impairment is more diffi cult because it may be confounded by depression or other psychological reactions to disease. Physical symptoms such as weakness, fatigue and dysarthria also obscure interpretation of items intended to determine if a patient is apathetic or withdrawn. Additionally, this aspect of screening relies on subjective informant reporting, which can be heterogeneous or inaccurate. This is a known factor in any study attempting to interpret caregiver-driven behavioral data or to establish base rates. The issue, which ultimately limits statistical power, is seen in other behavioral research in ALS (34) and other neurological disorders (35). Even taking this into account, there were signifi cant differences when comparing ALSbi with normal controls ( p ϭ 0.02), while the differences between behaviorally normal ALS patients and those with ALSbi ( p ϭ 0.15) and between ALS-impaired and ALS-FTD ( p ϭ 0.09) trended toward signifi cance. In our study, educational levels correlated with cognitive screen scores (Table IV) , a fi nding that is also expected in any cognitive evaluation. In our patients, however, the lowest cognitive scores were found in patients with frank FTD, who actually had educational levels similar to the remaining ALS cohort ( p ϭ 0.74) and higher than the general U.S. population. This likely refl ects our small sample size, but also the fact that patients with FTD were so severely impaired that any educational factors were overwhelmed by the degree of impairment. For patients with mild abnormalities, however, results do need to be interpreted in the context of educational background. In a similar vein, while screen scores did not correlate with age, it is known that elderly patients are at risk for non-FTD, global dementia, despite the diagnosis of ALS. As with any measure, results must be interpreted within the clinical context and supplementing screening with other measures such as the MMSE (8) or MOCA (36) that screen for memory and visuospatial skills may be necessary to resolve a wider differential diagnosis in certain cases.
We found another correlation between cognitive scores and FVC readings (Table IV) . One straightforward interpretation would be that respiratory dysfunction leading to poor oxygenation or, perhaps, anxiety, infl uenced the screen scores. However, we favor an alternative interpretation. Several studies have pointed to an association between bulbar involvement and impaired cognition in ALS (1, 37, 38) . It is also known that low FVCs may occur directly from bulbar involvement alone, presumably from altered airway and oral mechanics that affect the test even when there is no respiratory compromise (39). Thus, the correlation between cognition and FVC might be best explained by their parallel occurrence in patients who have signifi cant bulbar impairment, rather than as a direct causative mechanism.
In devising our test, we understood the trade-off between the number of items we could include and the time it takes to complete the measure in a busy clinical setting. With this in mind, we selected items that we thought were most likely to identify ALSrelated dementia and omitted questions that could assess other domains of cognition. This could be seen as a potential weakness. For example, we did not include memory items, which contradicts research showing that memory dysfunction can occur in this population (2,37). However, the effect on our screen may be limited because memory impairment in ALS is generally considered to be part of a frontally mediated syndrome and an amnestic process is not known to occur independently of the other frontally mediated abnormalities (2,37,40). The screen also fails to include confrontational naming items, although it does assess verbal fl uency and indirectly assesses semantic knowledge through commands and other instructions.
Two other studies have proposed longer screening measures that utilize a number of existing neuropsychiatric measures developed for a variety of patient populations (6,7). While these may address a wider number of defi cits, neither has been validated against a full neuropsychological battery to determine desirable cut-offs that predict impairment. Both studies supported their validity by showing that the percentage of ALS patients diagnosed with at least mild evidence of impairment was similar to studies that defi ned this prevalence using a comprehensive test battery. For comparison, using an optimal cognitive cut-off score of 16 or below on the ALS-CBS ™, 57% of our cohort would have been classifi ed as potentially cognitively impaired, which is also similar to these prevalence studies (1,2). The two existing screens for ALS also utilized a structured caregiver interview to assess behavior, which is time consuming and demands staff familiarity with behavioral interviewing (6,7), while the ALS-CBS™ uses a Likert scale that is completed by the caregiver at the same time that the patient is tested for cognition.
The small sample size of the validation cohort is another limitation of this study. A larger study could more clearly defi ne the receiver-operator characteristics across all screen scores and lend further support for the measure 's clinical utility. Nevertheless, screening for cognitive and behavioral impairments that may occur in ALS has now been recommended in the updated practice parameters (41), primarily because these patients are considered to be at risk for poor outcomes and decreased compliance with recommendations. Testing of any kind assures a formal approach so that cognition is certain to be assessed. On a practical level, from our own clinical experience, cognitive defi cits are usually clearly apparent in patients scoring at or below the cognitive cut-off of 10. In these cases, the screen tends to supplement our clinical intuition and helps steer the care team when serious recommendations are made. In contrast, borderline scores tend to have the effect of directly raising the possibility of impairment, and the highest scores tend to be reassuring when no signifi cant defi cit is suspected. As with any test score, no result is perfectly predictive, and acting on a result or deciding whether to perform more in-depth neuropsychological testing depends on available resources and considerations of how it would change management. As with any screening tool, the ALS-CBS™ does not replace formal assessment, and therefore diagnoses should not be provided to patients based on screen scores alone.
By shortening the screening time from 30 minutes in longer screens to only 5 minutes, the test has proven practical to perform in a busy clinical setting. The ease of use and the ability to be completed either verbally or non-verbally is also helpful in this population. The test may be particularly useful in clinical research settings where access to appropriate measures or personnel is often not available and repeated measures are necessary to detect changes and compare groups.
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